The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study

Shaoqing Zeng; Jianhua Chi; Jiahao Liu; Xiaofei Jiao; Xingyu Liu; Yang Yu; Ruyuan Li; Yabing Huo; Guanchen Ma; Yingjun Zhao; Li Wang; Qi Zhou; Dongling Zou; Xiaodong Cheng; Qingshui Li; Jing Wang; Shuzhong Yao; Weidong Zhao; Bairong Xia; Youguo Chen; Jiangtao Fan; Wei Wang; Li Hong; Ruixia Guo; Ziling Liu; Yunong Gao; Jundong Li; Bei Zhang; Jinjin Yu; Ting Hu; Wei Zhang; Wanying Shan; Zikun Peng; Ming Li; Xing Xie; Ding Ma; Qinglei Gao

doi:10.1111/1471-0528.17328

The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study

BJOG. 2022 Nov:129 Suppl 2:60-69. doi: 10.1111/1471-0528.17328.

Authors

Shaoqing Zeng^{1

2}, Jianhua Chi^{1

2}, Jiahao Liu^{1

2}, Xiaofei Jiao^{1

2}, Xingyu Liu^{1

2}, Yang Yu^{1

2}, Ruyuan Li^{1

2}, Yabing Huo^{1

2}, Guanchen Ma^{1

2}, Yingjun Zhao^{1

2}, Li Wang³, Qi Zhou^{4

5}, Dongling Zou^{4

5}, Xiaodong Cheng⁶, Qingshui Li⁷, Jing Wang^{8

9}, Shuzhong Yao¹⁰, Weidong Zhao^{11

12}, Bairong Xia¹¹, Youguo Chen¹³, Jiangtao Fan¹⁴, Wei Wang¹⁵, Li Hong¹⁶, Ruixia Guo¹⁷, Ziling Liu¹⁸, Yunong Gao¹⁹, Jundong Li^{20

21}, Bei Zhang²², Jinjin Yu²³, Ting Hu^{1

2}, Wei Zhang^{1

2}, Wanying Shan^{1

2}, Zikun Peng^{1

2}, Ming Li^{1

2}, Xing Xie^{1

6}, Ding Ma^{1

2}, Qinglei Gao^{1

2}

Affiliations

¹ National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
³ Department of Cancer Biology Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
⁴ Department of Gynecologic Oncology, Chongqing University Cancer Hospital, Chongqing, China.
⁵ Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
⁶ Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
⁷ Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, China.
⁸ Hunan Clinical Research Center in Gynecologic Cancer, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
⁹ Department of Gynecologic Cancer, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
¹⁰ Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
¹¹ Department of Gynecology and Oncology, Anhui Provincial Cancer Hospital, Hefei, China.
¹² Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
¹³ Department of Gynecology & Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, China.
¹⁴ Department of Gynecology, Guangxi Medical University First Affiliated Hospital, Nanning, China.
¹⁵ Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
¹⁶ Department of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, China.
¹⁷ Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
¹⁸ Department of Oncology, The First Hospital of Jilin University, Jilin, China.
¹⁹ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gynaecologic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
²⁰ Department of Gynecologic Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
²¹ State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, China.
²² Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, China.
²³ Department of Obstetrics and Gynecology, The Affiliated Hospital of Jiangnan University, Wuxi, China.

PMID: 36485066
DOI: 10.1111/1471-0528.17328

Abstract

Objective: To produce high-quality, real-world evidence for oncologists by collating scattered gynaecologic oncology (GO) medical records in China.

Design: Retrospective study.

Setting: The National Union of Real-world Gynaecological Oncology Research and Patient Management Platform (NUWA platform).

Sample: Patient-centred data pool.

Methods: The NUWA platform integrated inpatient/outpatient clinical, gene and follow-up data. Data of 11 456 patients with ovarian cancer (OC) were collected and processed using 91 345 electronic medical records. Structured and unstructured data were de-identified and re-collated into a patient-centred data pool using a predefined GO data model by technology-aided abstraction.

Main outcome measures: Recent treatment pattern shifts towards precision medicine for OC in China.

Results: Thirteen first-tier hospitals across China participated in the NUWA platform up to 7 December 2021. In total, 3504 (30.59%) patients were followed up by a stand-alone patient management centre. The percentage of patients undergoing breast cancer gene (BRCA) mutation tests increased by approximately six-fold between 2017 and 2018. A similar trend was observed in the administration rate of poly(ADP-ribose) polymerase inhibitors as first-line treatment and second-line treatment after September 2018, when olaparib was approved for clinical use in China.

Conclusion: The NUWA platform has great potential to facilitate clinical studies and support drug development, regulatory reviews and healthcare decision-making.

Keywords: breast cancer gene testing; gynaecologic oncology; ovarian cancer; real-world study; treatment patterns.

MeSH terms

China
East Asian People*
Female
Humans
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / genetics
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Retrospective Studies

Substances

Poly(ADP-ribose) Polymerase Inhibitors

Abstract

MeSH terms

Substances

Grants and funding